Oruka Therapeutics (ORKA) AI Stock Analysis

• Market Cap: $2.95B
• Dividend Yield: N/A
• Average Volume (3M): 530.53K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.04
• Revenue Growth: N/A
• EPS Growth: 63.85%
• Country: US
• Employees: 28
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.45
• Shares Outstanding: 49,542,690
• 10 Day Avg. Volume: 602,310
• 30 Day Avg. Volume: 530,527
• PEG Ratio: 0.24
• Price to Book (P/B): 2.93
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -15.64
• Enterprise Value/Market Cap: 0.76
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -80.49K
• Enterprise Value/Ebitda: -20.45
• 1Y Price Target: $76.64
• Price Target Upside: 28.63% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12
• EPS Forecast (FY): -2.33
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: $61.00 ▲(2.38% Upside)
• Action: Reiterated Date: 04/04/26
• Date: Action: Reiterated 04/04/26

The score is held back primarily by weak financial performance (no revenue, widening losses, and rising cash burn), partially offset by a strong solvency profile (low debt, sizable equity base). Technicals are supportive with a clear uptrend and positive momentum, but stretched momentum indicators add risk. Valuation is penalized due to ongoing losses and no dividend support.

Positive Factors

Strong solvency / low leverage

Very low leverage and a growing equity base provide durable financial flexibility for a clinical-stage biotech. This reduces bankruptcy and interest-rate risk, preserves optionality to fund trials or partner programs, and gives management time to advance assets before needing urgent refinancing.

Negative Factors

No revenue history

Absence of any product revenue means Oruka must rely on external capital and milestone/licensing events to sustain operations. This leaves commercial validation unproven, increases dependency on financing cycles, and prolongs cash runway risk until clinical success or partnerships materialize.

Oruka Therapeutics Business Overview & Revenue Model

Company Description

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA....

How the Company Makes Money

As a clinical-stage biotechnology company, Oruka Therapeutics does not have publicly available evidence of recurring product revenue from marketed therapies; as such, revenue from commercial drug sales is null. The company primarily funds operatio...

Read more

As a clinical-stage biotechnology company, Oruka Therapeutics does not have publicly available evidence of recurring product revenue from marketed therapies; as such, revenue from commercial drug sales is null. The company primarily funds operatio...

Oruka Therapeutics Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-83.00K	-27.00K	-114.00K	-91.00K	-93.00K
EBITDA	-121.97M	-82.23M	-9.81M	-19.23M	-9.64M
Net Income	-105.43M	-83.72M	-9.93M	-19.32M	-9.74M
Balance Sheet
Total Assets	488.62M	396.02M	43.09M	54.92M	50.43M
Cash, Cash Equivalents and Short-Term Investments	337.04M	375.65M	42.45M	53.36M	49.07M
Total Debt	1.93M	968.00K	383.00K	483.00K	450.00K
Total Liabilities	16.69M	13.80M	1.41M	3.88M	3.91M
Stockholders Equity	471.93M	382.22M	41.67M	51.04M	46.52M
Cash Flow
Free Cash Flow	-88.42M	-58.03M	-10.91M	-18.80M	-7.74M
Operating Cash Flow	-88.21M	-57.84M	-10.91M	-18.76M	-7.72M
Investing Cash Flow	-96.75M	-330.13M	-2.00K	-43.00K	-19.00K
Financing Cash Flow	170.31M	449.54M	0.00	23.09M	48.45M

Oruka Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 59.58
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORKA, the sentiment is Positive. The current price of 59.58 is above the 20-day moving average (MA) of 47.86, above the 50-day MA of 39.21, and above the 200-day MA of 26.52, indicating a bullish trend. The MACD of 6.61 indicates Negative momentum. The RSI at 73.27 is Negative, neither overbought nor oversold. The STOCH value of 86.63 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORKA.

Oruka Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BCAX	62 Neutral	$1.38B	-6.67	-32.49%	―	―	-103.95%
ORKA	55 Neutral	$2.95B	-13.11	-25.30%	―	―	63.85%
ANAB	53 Neutral	$2.02B	-101.81	1813.84%	―	196.42%	53.92%
CMPX	52 Neutral	$931.05M	-12.74	-43.61%	―	-100.00%	-28.79%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VSTM	49 Neutral	$466.40M	―	-1849.88%	―	33.79%	-26.37%
OLMA	47 Neutral	$1.40B	-13.39	-42.90%	―	―	17.23%